Atorvastatin + Evolocumab
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Conditions
Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events
Trial Timeline
Oct 1, 2013 → Jun 1, 2014
NCT ID
NCT01953328About Atorvastatin + Evolocumab
Atorvastatin + Evolocumab is a phase 3 stage product being developed by Amgen for Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events. The current trial status is completed. This product is registered under clinical trial identifier NCT01953328. Target conditions include Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01953328 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events